LINC01305 recruits basonuclin 1 to act on G‐protein pathway suppressor 1 to promote esophageal squamous cell carcinoma

Li Xiong,Jinsong Tan,Ruolan Zhang,Qiongxian Long,Rong Xiong,Yanqun Liu,Yun Liu,Jiancai Tang,Yan Li,Gang Feng,Guiqin Song,Kang Liu

DOI: https://doi.org/10.1111/cas.15963

IF: 5.7

2023-09-15

Cancer Science

Abstract:We screened the transcription factor basonuclin 1 (BNC1) to be highly expressed in esophageal squamous cell carcinoma (ESCC) by transcriptome sequencing of clinical samples and found that silencing BNC1 inhibited the malignant proliferation and metastasis ability of ESCC in vitro and in vivo. Furthermore, other experiments such as RNA immunoprecipitation, RNA pull‐down, and ChIP sequencing revealed and verified the molecular mechanism by which LINC01305 recruits BNC1 to act on the GPS1 promoter to promote JNK phosphorylation and then mediate the epithelial–mesenchymal transition process of ESCC. Finally, clinical analysis revealed that BNC1 expression was elevated in moderately and poorly differentiated and lymph node metastatic ESCC tissues, which has the potential as a clinical diagnostic marker and targeted therapy. EsophageaL squamous cell carcinoma (ESCC) is one of the most common and lethal tumors, however, its underlying molecular mechanisms are not completely understood and new therapeutic targets are needed. Here, we found that the transcription factor basonuclin 1 (BNC1) was significantly upregulated and closely related to the differentiation and metastasis of ESCC. Furthermore, BNC1, LINC01305, and G‐protein pathway suppressor 1 (GPS1) had significant oncogenic roles in ESCC. In addition, in vivo experiments showed that knockdown of BNC1 indeed significantly inhibited the proliferation and metastasis of ESCC. We also revealed the molecular mechanism by which LINC01305 recruits BNC1 to the promoter of GPS1, and then GPS1 could mediate the JNK signaling pathway to promote the proliferation and metastases of ESCC. Taken together, we discovered the novel molecular mechanism by which LINC01305/BNC1 upregulates GPS1 expression to promote the development of ESCC, providing a new therapeutic target for ESCC.

oncology